STARmed Thyroid Radiofrequency Ablation (RFA) was first introduced in 2002 in Seoul, South Korea. Today, with over 94+ clinical articles worldwide demonstrating the efficacy of this minimally invasive treatment, STARmed is leading the world with our cutting-edge thyroid RFA technology.
Americans have some form of thyroid disease, with the vast majority identified as benign lesions.
thyroid operations are performed each year in the United States.
thyroid resections are performed for benign diseases where patients could benefit from a less invasive option.
The Continuance Mode of the VIVA combo RF Generator produces radiofrequency (RF) output constantly throughout the procedure while automatically adjusting the amount of energy applied to the targeted nodule according to real-time impedance feedback. This innovative mechanism ensures the procedure’s safety by minimizing undesired tissue over-ablation.
The monopolar star RF Electrode stands out as the first thyroid-dedicated RF electrode in the market. It is uniquely designed with a shorter shaft length of 7 or 10 cm to accommodate the gland’s superficial location and a thinner shaft of 18 or 19 gauge for enhanced energy control. It comes with an array of active tip lengths at 4mm, 5mm, 7mm, and 10mm to cater to different nodule sizes.
The monopolar VIVA II RF Electrode is the latest innovation in RF ablation. It is the first of its kind, featuring an adjustable active tip ranging from 5mm to 30mm to accommodate multiple large nodules of varying sizes with one electrode in one session. Its latest sharp technology ensures a smooth puncture, while the smaller handle allows for greater precision control.
The Continuance Mode and the unique design of the STARmed RF Electrodes enable the Moving-Shot technique, which promotes ablation in units to limit thermal damage to surrounding tissue.
6 months after
STARmed Thyroid RFA
Individual results may vary.
Photo courtesy of Dr. Jung Hwan Baek
STARmed America is committed to refining the customer learning journey. We provide structured and measured procedure training programs for physicians and your care team.
The VIVA combo RF System is FDA-cleared and intended for use in percutaneous and intraoperative coagulation and ablation of tissue.